Charles Schwab
KITE

Charles Schwab’s Kite Pharma, Inc. KITE Stock Holding History

Charles Schwab’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-224,083
Closed -$40.3M – 3098
2017
Q3 		$40.3M Buy
224,083
+11,020
+5% +$1.54M 0.04% 506
2017
Q2 		$22.1M Buy
213,063
+22,589
+12% +$1.84M 0.02% 791
2017
Q1 		$15M Buy
190,474
+17,132
+10% +$1.06M 0.02% 1024
2016
Q4 		$7.77M Buy
173,342
+8,894
+5% +$436K 0.01% 1441
2016
Q3 		$9.19M Buy
164,448
+13,020
+9% +$725K 0.01% 1231
2016
Q2 		$7.57M Buy
151,428
+14,802
+11% +$727K 0.01% 1265
2016
Q1 		$6.27M Buy
136,626
+20,069
+17% +$972K 0.01% 1369
2015
Q4 		$7.18M Buy
116,557
+13,814
+13% +$972K 0.01% 1261
2015
Q3 		$5.72M Buy
102,743
+41,495
+68% +$2.61M 0.01% 1380
2015
Q2 		$3.73M Buy
61,248
+29,946
+96% +$1.71M 0.01% 1738
2015
Q1 		$1.81M Buy
31,302
+4,438
+17% +$297K ﹤0.01% 2110
2014
Q4 		$1.55M Buy
+26,864
New +$1.13M ﹤0.01% 2154

Charles Schwab's KITE Position: Q4 2017 in Review

Charles Schwab sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 224,083 shares — an estimated $40.3M sold.

Charles Schwab first reported a position in KITE in Q4 2014 and held it in 12 quarters. The position peaked at $40.3M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • Charles Schwab reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Charles Schwab sold 224,083 Kite Pharma, Inc. shares in Q4 2017, an estimated $40.3M.
  • Charles Schwab first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 12 quarters.
  • Charles Schwab's Kite Pharma, Inc. position peaked at $40.3M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Charles Schwab's 13F filing for Q4 2017, filed 17 Jan 2018.